Humanized Mouse Model of Ovarian Cancer Recapitulates Patient Solid Tumor Progression, Ascites Formation, and Metastasis

Ovarian cancer is the most common cause of death from gynecological cancer. Understanding the biology of this disease, particularly how tumor-associated lymphocytes and fibroblasts contribute to the progression and metastasis of the tumor, has been impeded by the lack of a suitable tumor xenograft model. We report a simple and reproducible system in which the tumor and tumor stroma are successfully engrafted into NOD-scid IL2Rγnull (NSG) mice. This is achieved by injecting tumor cell aggregates derived from fresh ovarian tumor biopsy tissues (including tumor cells, and tumor-associated lymphocytes and fibroblasts) i.p. into NSG mice. Tumor progression in these mice closely parallels many of the events that are observed in ovarian cancer patients. Tumors establish in the omentum, ovaries, liver, spleen, uterus, and pancreas. Tumor growth is initially very slow and progressive within the peritoneal cavity with an ultimate development of tumor ascites, spontaneous metastasis to the lung, increasing serum and ascites levels of CA125, and the retention of tumor-associated human fibroblasts and lymphocytes that remain functional and responsive to cytokines for prolonged periods. With this model one will be able to determine how fibroblasts and lymphocytes within the tumor microenvironment may contribute to tumor growth and metastasis, and will make it possible to evaluate the efficacy of therapies that are designed to target these cells in the tumor stroma.

[1]  E. Baracat,et al.  Fallopian tube origin of supposed ovarian high‐grade serous carcinomas , 2011, Clinics.

[2]  M. Allen,et al.  Jekyll and Hyde: the role of the microenvironment on the progression of cancer , 2011, The Journal of pathology.

[3]  Jennifer A. Prescher,et al.  Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models , 2010, Proceedings of the National Academy of Sciences.

[4]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[5]  R. J. Kelleher,et al.  Reciprocal Functional Modulation of the Activation of T Lymphocytes and Fibroblasts Derived from Human Solid Tumors , 2010, The Journal of Immunology.

[6]  Lloyd J. Old,et al.  Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer , 2010, Proceedings of the National Academy of Sciences.

[7]  R. J. Kelleher,et al.  T Cells and Stromal Fibroblasts in Human Tumor Microenvironments Represent Potential Therapeutic Targets , 2010, Cancer Microenvironment.

[8]  C. Rinker-Schaeffer,et al.  Disrupting Ovarian Cancer Metastatic Colonization: Insights from Metastasis Suppressor Studies , 2010, Journal of oncology.

[9]  Peter Olson,et al.  Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. , 2010, Cancer cell.

[10]  D. Gupta,et al.  Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature , 2009, Journal of ovarian research.

[11]  R. J. Kelleher,et al.  IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. , 2009, Clinical immunology.

[12]  S. Gerber,et al.  Omental immune aggregates and tumor metastasis within the peritoneal cavity , 2009, Immunologic research.

[13]  R. Drapkin,et al.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Odunsi,et al.  Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer , 2008, Proceedings of the National Academy of Sciences.

[15]  T. Whiteside.  The tumor microenvironment and its role in promoting tumor growth , 2008, Oncogene.

[16]  R. J. Kelleher,et al.  Long-Term Engraftment and Expansion of Tumor-Derived Memory T Cells Following the Implantation of Non-Disrupted Pieces of Human Lung Tumor into NOD-scid IL2Rγnull Mice1 , 2008, The Journal of Immunology.

[17]  A. Nauta,et al.  Immunomodulatory properties of mesenchymal stromal cells. , 2007, Blood.

[18]  A. Ayhan,et al.  Omentectomy for gynecologic cancer: how much sampling is adequate for microscopic examination? , 2007, Archives of pathology & laboratory medicine.

[19]  G. Zhu,et al.  Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. , 2007, Cancer research.

[20]  R. J. Kelleher,et al.  Response to Comment on “Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells” , 2007, The Journal of Immunology.

[21]  Dale L. Greiner,et al.  Humanized mice in translational biomedical research , 2007, Nature Reviews Immunology.

[22]  R. Weichselbaum,et al.  Induced sensitization of tumor stroma leads to eradication of established cancer by T cells , 2007, The Journal of experimental medicine.

[23]  Scott A Gerber,et al.  Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. , 2006, The American journal of pathology.

[24]  J. Bernstein,et al.  IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. , 2006, Clinical immunology.

[25]  J. Manson,et al.  Use of a dummy (pacifier) during sleep and risk of sudden infant death syndrome (SIDS): population based case-control study , 2005, BMJ : British Medical Journal.

[26]  E. Mathiowitz,et al.  IL-12 + GM-CSF Microsphere Therapy Induces Eradication of Advanced Spontaneous Tumors in her-2/neu Transgenic Mice But Fails to Achieve Long-Term Cure Due to the Inability to Maintain Effector T-Cell Activity , 2006, Journal of immunotherapy.

[27]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Gilks,et al.  An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line , 2005, Laboratory Investigation.

[29]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[30]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[31]  M. Sabel,et al.  Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. , 2002, Cancer research.

[32]  S. D. Hess,et al.  Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. , 2001, Trends in immunology.

[33]  G. Coukos,et al.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.

[34]  A. van Dalen,et al.  Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. , 2000, Gynecologic oncology.

[35]  H. Ngan,et al.  FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. , 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[36]  H. Ngan,et al.  FIGO staging classifications and clinical practice gudelines in the management of gynecologic cancers , 2000 .

[37]  M. Sabel,et al.  In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. , 2000, Cancer research.

[38]  P. Klenerman,et al.  Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Aune,et al.  Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines , 1993, Journal of leukocyte biology.

[40]  H. Schreiber,et al.  Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells , 1992, The Journal of experimental medicine.

[41]  G. Spiegel,et al.  Stage I endometrial carcinoma. Role of omental biopsy and omentectomy. , 1991, The Journal of reproductive medicine.

[42]  H. Takita,et al.  Human lung tumor growth established in the lung and subcutaneous tissue of mice with severe combined immunodeficiency. , 1987, Cancer research.

[43]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[44]  M. Simpson-Abelson,et al.  Targeting the TCR signaling checkpoint: a therapeutic strategy to reactivate memory T cells in the tumor microenvironment. , 2008, Expert opinion on therapeutic targets.

[45]  Mark Shackleton,et al.  Efficient tumour formation by single human melanoma cells , 2008 .

[46]  Chen Jianhua,et al.  Establishment of orthotopic transplantation model of human bladder cancer and detection by MRI , 2008 .

[47]  D. Wen,et al.  Establishment of orthotopic transplantation model of human bladder cancer and detection by MRI , 2008 .